9:02AM Seattle Genetics to present clinical data from broad ADCETRIS development program and novel antibody-drug conjugate sgn-cd19a at ash 2013; data support goal to establish adcetris as the foundation of therapy for cd30-positive malignancies (SGEN) 38.92 : Co announced that multiple abstracts will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following:
Clinical data for ADCETRIS (brentuximab vedotin) in CD30-positive lymphomas, including Hodgkin lymphoma (HL), mature T-cell lymphoma (MTCL), cutaneous T-cell lymphoma (CTCL) and diffuse B-cell lymphoma (DLBCL)
Interim phase 1 clinical data for SGN-CD19A, a novel antibody-drug conjugate (ADC), in acute lymphoblastic leukemia (ALL)
Final phase 1 data from two ADC candidates that utilize Seattle Genetics' proprietary technology being developed by Genentech, a member of the Roche Group (SIC: RO, ROG; OTCQX: RHHBY), including an anti-CD22 ADC (pinatuzumab vedotin, RG7593) and an anti-CD79b ADC (polatuzumab vedotin, RG7596).
SGN-CD19A is an ADC targeting CD19, a protein expressed broadly on B-cell malignancies. Preclinical data presented at the 2011 American Association for Cancer Research Annual Meeting demonstrated that SGN-CD19A effectively binds to target cells, internalizes and induces potent cell-killing activity and durable tumor regressions at low doses in multiple cancer models. SGN-CD19A is being evaluated in two ongoing phase 1 clinical trials for patients with B-cell ALL and aggressive non-Hodgkin lymphoma (NHL).
News 
Market Data 
Discover 
